enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Selexipag - Wikipedia

   en.wikipedia.org/wiki/Selexipag

   Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]

3. Iloprost - Wikipedia

   en.wikipedia.org/wiki/Iloprost

   Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. [4] Iloprost is a prostacyclin mimetic. [1]

4. Sotatercept - Wikipedia

   en.wikipedia.org/wiki/Sotatercept

   Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [6] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [9]

5. What You Need to Know About PAH Drugs in 2014 - AOL

   www.aol.com/2013/12/31/what-you-need-to-know...

   A host of newly approved drugs for pulmonary arterial hypertension, or PAH, means 2014 will be a battleground for market share in the multibillion-dollar indication. Among those competing will be ...

6. Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

   www.aol.com/news/arena-arna-licenses-rights-pah...

   Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

7. Riociguat - Wikipedia

   en.wikipedia.org/wiki/Riociguat

   The Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial (CHEST) was a randomized, placebo-controlled trial aimed to analyse the efficacy and safety of riociguat in CTEPH patients. [20] After a 16-week riociguat treatment the patient's exercise capacity were evaluated by measuring the change in the six-minute walk test (6-MWT). [ 21 ]

8. Macitentan - Wikipedia

   en.wikipedia.org/wiki/Macitentan

   Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B . [ 5 ]

9. What's the strongest OTC anti-inflammatory? Experts ... - AOL

   www.aol.com/whats-strongest-otc-anti...

   According to Cleveland Clinic, you should also avoid taking NSAIDs if you are pregnant, or have a history of stroke or heart attack, heart failure, stomach ulcers, Crohn’s disease or ulcerative ...